Regenerative medicine company FibroBiologics (stock code: FBLG) recently filed documents with the U.S. Securities and Exchange Commission (SEC), announcing that it has signed an At Market Issuance (ATM) agreement.

According to the agreement, the company is authorized to issue up to $6.15 million worth of common stock through an underwriter. The ATM issuance mechanism allows listed companies to flexibly issue new shares based on market conditions, which will provide FibroBiologics with additional operating capital. The company focuses on developing innovative therapies for chronic diseases using fibroblast technology, and this financing will accelerate the clinical advancement of its cell therapy pipeline. The specific terms of this issuance will depend on market conditions, share price fluctuations, and the company's capital requirements. Through this equity financing approach, FibroBiologics is expected to maintain financial flexibility while supporting long-term R&D investments.